S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

$9.86
+0.16 (+1.65%)
(As of 02/23/2024 ET)
Today's Range
$9.34
$10.00
50-Day Range
$3.67
$9.86
52-Week Range
$2.00
$10.00
Volume
3.96 million shs
Average Volume
1.84 million shs
Market Capitalization
$783.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.5% Upside
$14.25 Price Target
Short Interest
Healthy
4.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.50mentions of Ocular Therapeutix in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$194,862 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.12) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.26 out of 5 stars

Medical Sector

130th out of 941 stocks

Pharmaceutical Preparations Industry

51st out of 428 stocks


OCUL stock logo

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

OCUL Stock News Headlines

StockNews.com Lowers Ocular Therapeutix (NASDAQ:OCUL) to Sell
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
OCUL Mar 2024 7.000 put
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
OCUL Mar 2024 4.000 put
Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright
Ocular Therapeutix Inc (OCUL)
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/23/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUL
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$18.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+44.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-71,040,000.00
Net Margins
-116.18%
Pretax Margin
-116.18%

Debt

Sales & Book Value

Annual Sales
$51.49 million
Book Value
$0.46 per share

Miscellaneous

Free Float
75,051,000
Market Cap
$783.08 million
Optionable
Optionable
Beta
1.09
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 56)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Rabia Gurses Ozden M.D. (Age 56)
    Chief Medical Officer
    Comp: $621.39k
  • Dr. Peter K. Jarrett Ph.D. (Age 67)
    Chief Scientific Officer
  • Mr. Philip C. Strassburger Esq. (Age 64)
    General Counsel
    Comp: $282.61k
  • Mr. William H. Ransone II
    Vice President of Global Sales & Marketing
  • Ms. Tracy Smith
    Vice President of Human Resources
  • Mr. Christopher G. White (Age 62)
    Chief Business Officer
  • Dr. Karen-Leigh Edwards M.B.A.
    Ph.D., Senior Vice President of Technical Operations
  • Dr. Peter K. Kaiser M.D.
    Chief Medical Advisor of Retina














OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price target for 2024?

4 Wall Street research analysts have issued 12 month target prices for Ocular Therapeutix's shares. Their OCUL share price targets range from $12.00 to $18.00. On average, they expect the company's share price to reach $14.25 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 on January 1st, 2024. Since then, OCUL shares have increased by 121.1% and is now trading at $9.86.
View the best growth stocks for 2024 here
.

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a increase in short interest in January. As of January 31st, there was short interest totaling 3,960,000 shares, an increase of 18.2% from the January 15th total of 3,350,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 2.9 days.
View Ocular Therapeutix's Short Interest
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analysts' expectations of $12.13 million. Ocular Therapeutix had a negative net margin of 116.18% and a negative trailing twelve-month return on equity of 589.24%. During the same period in the prior year, the business earned ($0.17) EPS.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (7.64%), Vanguard Group Inc. (6.44%), Franklin Resources Inc. (5.67%), Deltec Asset Management LLC (3.08%), Nuveen Asset Management LLC (1.27%) and Great Point Partners LLC (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 2/24/2024 by MarketBeat.com Staff